EMA publishes EPAR for Aerivio Spiromax

5 September 2016 - The EMA has published an EPAR for Teva Pharmaceuticals' version of GSK's Seretide/Advair. ...

Read more →

European Commission grants marketing authorisation for Teva’s Cinqaero (reslizumab)

18 August 2016 - First intravenous anti-IL-5 biologic therapy for severe eosinophilic asthma now approved in Europe. ...

Read more →

Novartis announces FDA approval of Xolair (omalizumab) for paediatric allergic asthma

7 July 2016 - Extension of indication makes Xolair the first and only approved biologic for pediatric patients six years and ...

Read more →

Teva receives CHMP positive opinion for Cinqaero (reslizumab)

24 June 2016 - Add-on therapy targeting IL-5 in adults with severe eosinophilic asthma pending marketing authorization in Europe. ...

Read more →

NICE publishes second appraisal consultation for Nucala (mepolizumab)

9 June 2016 - NICE has published a second appraisal consultation for GSK's Nucala (mepolizumab). ...

Read more →

Schedule of Pharmaceutical Benefits - 1 June 2016 update

1 June 2016 - The June 2016 issue of the Schedule is out and now in effect. ...

Read more →

Prescription medicines: new or extended uses approved by the TGA

17 May 2016 - The TGA has published a list of the medicines it approved for new uses (new indications) ...

Read more →

Call for patient input on a submission from Teva Pharmaceuticals for reslizumab

4 May 2016 - CADTH has received notice of a pending submission from Teva Pharmaceuticals for reslizumab for use by patients ...

Read more →

Mepolizumab in severe asthma: additional benefit is not proven

2 May 2016 - Appropriate comparator therapy not implemented so the indirect comparison is unsuitable. ...

Read more →

Teva announces FDA approval of ProAir RespiClick (salbutamol sulphate) inhalation powder for paediatric asthma patients ages 4 to 11

29 April 2016 - Teva Pharmaceuticals announced today that the U.S. FDA has approved ProAir RespiClick (salbutamol sulphate) inhalation powder for ...

Read more →

NICE appraisal consultation for mepolizumab (Nucala) for patients with severe eosinophilic asthma

4 April 2016 - The Department of Health has asked NICE to produce guidance on using mepolizumab in the NHS in ...

Read more →

FDA approves Cinqair to treat severe asthma

23 March 2016 - The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for ...

Read more →

New Zealand Pharmaceutical Schedule - 1 March 2016 update

1 March 2016 - the March 2016 issue of the Schedule sees the listing of a number of new medicines/combination ...

Read more →

Budesonide with eformoterol (Symbicort Turbuhaler and Vannair) proposal with Astra Zeneca

15 December 2015 - PHARMAC is seeking feedback on a proposal involving budesonide with eformoterol inhalers (Symbicort Turbuhaler and Vannair), which ...

Read more →

CADTH calls for patient input on a new submission from GSK for mepolizumab

20 November 2015 - CADTH has received notice of a pending submission from GSK for mepolizumab for use by patients with ...

Read more →